NBIX News and Press, Neurocrine Biosciences Inc. From 11/03/22

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsules at the American Society of Consultant Pharmacists (ASCP) 2022 Annual Meeting PR Newswire SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Neurocrin...

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022 PR Newswire SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBI...

Neurocrine Biosciences ( NASDAQ: NBIX ) stock rose ~6% on Tuesday after the company reported Q3 results and raised FY22 sales outlook for its drug Ingrezza. Q3 non-GAAP EPS grew +68.75% Y/Y to $1.08, but missed analysts' estimates. Total revenues grew +31% Y/...

Neurocrine Biosciences, Inc. (NBIX) Q3 2022 Earnings Conference Call November 1, 2022 08:00 AM ET Company Participants Todd Tushla - VP of IR Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Off...

Neurocrine Biosciences press release ( NASDAQ: NBIX ): Q3 Non-GAAP EPS of $1.08 misses by $0.04 . Revenue of $387.9M (+31.0% Y/Y) beats by $11.15M . INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $376 Million INGREZZA ® ...

Neurocrine Biosciences Reports Third Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $376 Million INGREZZA ® (valbenazine) 2022 Net Produc...

Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia PR Newswire NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist SAN DIEGO , Oct. 27, 2022 /PRNewswire/ -...

Neurocrine Biosciences Presents Real-World Parkinson's Disease Patient Characteristics From ONGENTYS® (opicapone) Open-Label Study at ANA2022 PR Newswire SAN DIEGO , Oct. 24, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today ...

Summary HQH is able to generate strong and steady yield which is good enough to ignore the price loss suffered by this fund in a market that’s bearish overall. HQH is in a better position to hold up to its current price, and as it trades at a good discount to its NAV, chanc...

Neurocrine Biosciences Presents Data on Benztropine Use Among People Treated with Antipsychotics at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference PR Newswire SAN DIEGO , Oct. 19, 2022 /PRNewswire/ -- Neurocrine Biosciences, I...